A prespecified analysis of the SURPASS-CVOT trial assessed the efficacy and safety of tirzepatide compared with dulaglutide on kidney outcomes in patients with very high-risk CKD and type 2 diabetes.
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on CKD, today presented full results from the Phase 2 REGEN-007 trial ...
Compelling kidney function data from VIVIAD Phase 2b study presented in late-breaking poster at ASN kidney week, the world’s premier nephrology meeting VIVIAD analyses continue to support ...
Please provide your email address to receive an email when new articles are posted on . The clinical benefits of tirzepatide in patients with HFpEF and obesity were consistent regardless of kidney ...
Proton pump inhibitors (PPIs) do not appear to worsen kidney function compared with the histamine 2 receptor blocker ranitidine based on two measures, a large cohort study from Spain finds. In fact, ...
Heart failure patients treated with finerenone (Kerendia; Bayer AG) are more likely to have an early decline in kidney function than those treated with placebo, but the decline should not be construed ...
A study of real-world patients with ADPKD supports tolvaptan’s role in slowing annual eGFR decline. Treatment with tolvaptan modestly but significantly attenuates long-term decline of kidney function ...
Chronic kidney disease (CKD) affects more than 700 million people worldwide and is caused by genetic and environmental factors, as well as existing medical conditions. Known genetic risk factors for ...
New information to be presented on the study design and methodology of Purespring’s Phase I/IItrial of PS-002, an AAV-based therapy delivering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback